144 related articles for article (PubMed ID: 35796018)
1. Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation.
Navalkar A; Paul A; Sakunthala A; Pandey S; Dey AK; Saha S; Sahoo S; Jolly MK; Maiti TK; Maji SK
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35796018
[TBL] [Abstract][Full Text] [Related]
2. Direct evidence of cellular transformation by prion-like p53 amyloid infection.
Navalkar A; Pandey S; Singh N; Patel K; Datta D; Mohanty B; Jadhav S; Chaudhari P; Maji SK
J Cell Sci; 2021 Jun; 134(11):. PubMed ID: 34085695
[TBL] [Abstract][Full Text] [Related]
3. p53 induces transcriptional and translational programs to suppress cell proliferation and growth.
Loayza-Puch F; Drost J; Rooijers K; Lopes R; Elkon R; Agami R
Genome Biol; 2013 Apr; 14(4):R32. PubMed ID: 23594524
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
5. Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.
Bigi A; Beltrami E; Trinei M; Stendardo M; Pelicci PG; Giorgio M
Oncogene; 2016 Sep; 35(39):5132-43. PubMed ID: 26973251
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
7. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
9. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
Singh S; Kumar M; Kumar S; Sen S; Upadhyay P; Bhattacharjee S; M N; Tomar VS; Roy S; Dutt A; Kundu TK
J Biol Chem; 2019 Sep; 294(38):14081-14095. PubMed ID: 31366730
[TBL] [Abstract][Full Text] [Related]
10. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor p53 and its gain-of-function mutants in cancer.
Liu J; Zhang C; Feng Z
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor p53 and its mutants in cancer metabolism.
Liu J; Zhang C; Hu W; Feng Z
Cancer Lett; 2015 Jan; 356(2 Pt A):197-203. PubMed ID: 24374014
[TBL] [Abstract][Full Text] [Related]
13. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
14. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
Petrenko O; Zaika A; Moll UM
Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
[TBL] [Abstract][Full Text] [Related]
15. Amyloid Evolvability and Cancer.
Takamatsu Y; Ho G; Hashimoto M
Trends Cancer; 2020 Aug; 6(8):624-627. PubMed ID: 32386876
[TBL] [Abstract][Full Text] [Related]
16. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.
Avery-Kiejda KA; Bowden NA; Croft AJ; Scurr LL; Kairupan CF; Ashton KA; Talseth-Palmer BA; Rizos H; Zhang XD; Scott RJ; Hersey P
BMC Cancer; 2011 May; 11():203. PubMed ID: 21615965
[TBL] [Abstract][Full Text] [Related]
17. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
Tolbert D; Lu X; Yin C; Tantama M; Van Dyke T
Mol Cell Biol; 2002 Jan; 22(1):370-7. PubMed ID: 11739748
[TBL] [Abstract][Full Text] [Related]
18. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.
Ferraiuolo M; Verduci L; Blandino G; Strano S
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467351
[TBL] [Abstract][Full Text] [Related]
20. Amyloids and brain cancer: molecular linkages and crossovers.
Singh S; Joshi V; Upadhyay A
Biosci Rep; 2023 Oct; 43(10):. PubMed ID: 37335084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
